Laboratorios Farmaceuticos Rovi Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Juan Lopez-Belmonte Encina
Algemeen directeur
€1.3m
Totale compensatie
| Percentage CEO-salaris | 55.2% |
| Dienstverband CEO | 17.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 5.5yrs |
Recente managementupdates
Recent updates
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 10
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
Oct 21Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Aug 29Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €165m |
| Jun 30 2024 | n/a | n/a | €148m |
| Mar 31 2024 | n/a | n/a | €138m |
| Dec 31 2023 | €1m | €743k | €170m |
| Sep 30 2023 | n/a | n/a | €197m |
| Jun 30 2023 | n/a | n/a | €186m |
| Mar 31 2023 | n/a | n/a | €194m |
| Dec 31 2022 | €1m | €728k | €200m |
| Sep 30 2022 | n/a | n/a | €176m |
| Jun 30 2022 | n/a | n/a | €183m |
| Mar 31 2022 | n/a | n/a | €182m |
| Dec 31 2021 | €2m | €327k | €153m |
| Sep 30 2021 | n/a | n/a | €113m |
| Jun 30 2021 | n/a | n/a | €82m |
| Mar 31 2021 | n/a | n/a | €71m |
| Dec 31 2020 | €561k | €330k | €61m |
| Sep 30 2020 | n/a | n/a | €55m |
| Jun 30 2020 | n/a | n/a | €53m |
| Mar 31 2020 | n/a | n/a | €46m |
| Dec 31 2019 | €541k | €320k | €39m |
| Sep 30 2019 | n/a | n/a | €33m |
| Jun 30 2019 | n/a | n/a | €27m |
| Mar 31 2019 | n/a | n/a | €18m |
| Dec 31 2018 | €908k | €312k | €18m |
| Sep 30 2018 | n/a | n/a | €16m |
| Jun 30 2018 | n/a | n/a | €9m |
| Mar 31 2018 | n/a | n/a | €18m |
| Dec 31 2017 | €524k | €303k | €17m |
Compensatie versus markt: De totale vergoeding ($USD 1.41M ) Juan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Spanish markt ($USD 1.54M ).
Compensatie versus inkomsten: De vergoeding van Juan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Juan Lopez-Belmonte Encina
17.8yrs
Tenure
€1,346,000
Compensatie
Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 17.3yrs | €1.35m | geen gegevens | |
| Second Deputy Chairman & GM of Commercial and Development | 17.3yrs | €552.00k | geen gegevens | |
| First Deputy Chairman | 17.3yrs | €554.00k | geen gegevens | |
| Independent Director | 5.5yrs | €80.00k | geen gegevens | |
| Independent Director | 4.9yrs | €80.00k | geen gegevens | |
| Director | 2.5yrs | €80.00k | geen gegevens | |
| Independent Director | 1.9yrs | €80.00k | geen gegevens |
5.5yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van ROVI wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).